{
  "source": "PA-Notification-Zolinza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1329-6\nProgram Prior Authorization/Notification\nMedication Zolinza® (vorinostat)\nP&T Approval Date 9/2020, 9/2021, 10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nZolinza® (vorinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of\ncutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have\nprogressive, persistent, or recurrent disease on or following two systemic therapies. The National\nCancer Comprehensive Network (NCCN) also recommends the use of Zolinza as a systemic\ntherapy as primary treatment or subsequent for cutaneous T-cell lymphoma (CTCL).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Zolinza will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Cutaneous T-cell Lymphoma (CTCL)\n1. Initial Authorization\na. Zolinza will be approved based on the following criteria:\n(1) Diagnosis of cutaneous T-cell Lymphoma (CTCL)\n-AND-\n(2) Patient has progressive, persistent, or recurrent disease on or following two\nsystemic therapies [e.g., Adcetris (brentuximab vedotin), bexarotene, interferon\nalfa-db, interferon gamma-1b, methotrexate, Poteligeo (mogamulizumab),\n© 2024 UnitedHealthcare Services, Inc.\n1\nromidepsin]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zolinza will be approved based on the following criterion:\n(1) Pati",
    "gamulizumab),\n© 2024 UnitedHealthcare Services, Inc.\n1\nromidepsin]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zolinza will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zolinza therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Zolinza [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; July 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nAugust 29, 2024.\nProgram Prior Authorization/Notification – Zolinza® (vorinostat)\nChange Control\n9/2020 New program.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreferences.\n10/2021 Updated criteria to align with label. Updated references.\n10/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote. Updated references.\n10/2023 Annual review with no changes to coverage criteria. Updated\n© 2024 UnitedHealthcare Services, Inc.\n2\nreferences.\n10/2024 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n",
    "eview with no changes to coverage criteria. Updated\n© 2024 UnitedHealthcare Services, Inc.\n2\nreferences.\n10/2024 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}